These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37311949)

  • 1. Dopaminergic treatment strategies for people with Parkinson's disease in Europe: a retrospective analysis of PRISM trial data.
    Hansen L; Witzig V; Schulz JB; Holtbernd F
    Neurol Sci; 2023 Nov; 44(11):3905-3912. PubMed ID: 37311949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Parkinson's Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson's Disease in Patients and their Carers.
    Tolosa E; Ebersbach G; Ferreira JJ; Rascol O; Antonini A; Foltynie T; Gibson R; Magalhaes D; Rocha JF; Lees A
    J Parkinsons Dis; 2021; 11(3):1309-1323. PubMed ID: 34024784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescribing patterns and determinants for elderly patients with Parkinson's disease in Japan: a retrospective observational study using insurance claims databases.
    Seki M; Kawata Y; Hayashi A; Arai M; Fujimoto S
    Front Neurol; 2023; 14():1162016. PubMed ID: 37426443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa-induced dyskinesia in Parkinson's disease: still no proof? A meta-analysis.
    Giannakis A; Chondrogiorgi M; Tsironis C; Tatsioni A; Konitsiotis S
    J Neural Transm (Vienna); 2018 Sep; 125(9):1341-1349. PubMed ID: 29352351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
    Markham A; Benfield P
    CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease severity and use of dopaminergic medications.
    Fang JY; Pérez A; Christine CW; Leehey M; Aminoff MJ; Boyd JT; Morgan JC; Dhall R; Nicholas AP; Bodis-Wollner I; Zweig RM; Goudreau JL;
    Parkinsonism Relat Disord; 2015 Mar; 21(3):297-9. PubMed ID: 25541182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Prescription Patterns For Patients With Young-Onset Parkinson's Disease in China: A Trend Analysis From 2014 to 2019.
    Liu XQ; Wang XY; Shen HM; Pang WY; Zhong MK; Ma CL
    Front Pharmacol; 2022; 13():858139. PubMed ID: 35645835
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study.
    Pellicano C; Benincasa D; Fanciulli A; Latino P; Giovannelli M; Pontieri FE
    Eur J Med Res; 2013 Dec; 18(1):60. PubMed ID: 24360350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database.
    Suzuki M; Arai M; Hayashi A; Ogino M
    eNeurologicalSci; 2020 Sep; 20():100257. PubMed ID: 32775705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill
    LeWitt PA; Giladi N; Navon N
    Parkinsonism Relat Disord; 2019 Aug; 65():131-138. PubMed ID: 31176632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Systematic evaluation on influence of dopaminergic therapy: on motor complications in Parkinson's disease].
    Zhou MZ; Liu ZG; Chen W; Lu LX; Wu JY; Qi C
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):438-44. PubMed ID: 19567089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications.
    Adamiak-Giera U; Jawień W; Pierzchlińska A; Białecka M; Kobierski JD; Janus T; Gawrońska-Szklarz B
    Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson's Disease.
    Conti V; Izzo V; Russillo MC; Picillo M; Amboni M; Scaglione CLM; Nicoletti A; Cani I; Cicero CE; De Bellis E; Charlier B; Giudice V; Somma G; Corbi G; Barone P; Filippelli A; Pellecchia MT
    Front Med (Lausanne); 2022; 9():909936. PubMed ID: 35712091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®).
    Hauser RA; Zeitlin L; Fisher S; D'Souza R
    Parkinsonism Relat Disord; 2021 Jan; 82():133-137. PubMed ID: 33360173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease.
    van Hilten JJ; Ramaker CC; Stowe R; Ives NJ
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD003634. PubMed ID: 17943795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease.
    Ramaker C; Hilten JJ
    Cochrane Database Syst Rev; 2002; (2):CD003634. PubMed ID: 12076493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study.
    Lennert B; Bibeau W; Farrelly E; Sacco P; Schoor T
    Am Health Drug Benefits; 2012 Sep; 5(6):347-58. PubMed ID: 24991332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.